Meeting
2021 Genitourinary Cancers Symposium
Comparative analysis of sarcopenia induced by long-term abiraterone (A) versus enzalutamide (E) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Mahdi Farzad Naimi
Odette Cancer Centre, Toronto, ON, Canada
Mahdi Farzad Naimi , Maira Khan , Juan Rodrigo Briones Carvajal , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 69)
DOI
10.1200/JCO.2021.39.6_suppl.69
Abstract #
69
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo